Suchergebnisse - "Ikeda, Masanori"

PubPharm (361)

1

Development and validation of a new asthma questionnaire to help achieve a high level of control in school-age children and adolescents

enthalten in: Allergology international : official journal of the Japanese Society of Allergology | 2024

von Matsunaga, M. | Sato, Y. | Nagao, M. | +8

2

Benralizumab in children with severe eosinophilic asthma : Pharmacokinetics and long-term safety (TATE study)

enthalten in: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology | 2024

von Wedner, H. | Fujisawa, T. | Guilbert, T. | +12

3

Hepatitis C virus NS5B triggers an MDA5-mediated innate immune response by producing dsRNA without the replication of viral genomes

enthalten in: The FEBS journal | 2024

von Dansako, H. | Ikeda, M. | Ariumi, Y. | +2

4

DEVELOPMENT AND VALIDATION OF QUALITY OF LIFE QUESTIONNAIRE FOR PARENT BURDEN OF CHILDREN WITH FOOD ALLERGY

enthalten in: Arerugi = [Allergy | 2024

von Kawano, T. | Takase, A. | Yasunari, D. | +10

5

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan : Analysis of the 3-Year Phase 3 Rising Up Study

enthalten in: Dermatology and therapy | 2024

von Katoh, N. | Ikeda, M. | Ohya, Y. | +7

6

Identification of dihydroorotate dehydrogenase inhibitor, vidofludimus, as a potent and novel inhibitor for influenza virus

enthalten in: Journal of medical virology | 2024

von Li, J. | Takeda, M. | Imahatakenaka, M. | +1

7

Identification of dihydroorotate dehydrogenase inhibitor, vidofludimus, as a potent and novel inhibitor for influenza virus

enthalten in: Journal of Medical Virology | 2024

von Li, J. | Takeda, M. | Imahatakenaka, M. | +1

8

Benralizumab in children with severe eosinophilic asthma : Pharmacokinetics and long‐term safety ( TATE study)

enthalten in: Pediatric Allergy and Immunology | 2024

von Wedner, H. | Fujisawa, T. | Guilbert, T. | +11

9

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study

enthalten in: Dermatology and therapy | 2023

von Katoh, N. | Ikeda, M. | Ohya, Y. | +7

10

Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus : results from a phase III, randomized, double-blind, placebo-controlled, multicentre study

enthalten in: The British journal of dermatology | 2023

von Igarashi, A. | Katsunuma, T. | Matsumura, T. | +43

CommentIn: Br J Dermatol. 2023 Sep 02;:. - PMID 37658936

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[37]